FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2800604403> ?p ?o ?g. }

• W2800604403 endingPage "7" @default.
• W2800604403 startingPage "1" @default.
• W2800604403 abstract "Abstract Background 5‐Fluorouracil (5‐FU) and capecitabine‐associated cardiotoxicity ranging from asymptomatic electrocardiography (ECG) abnormalities to severe myocardial infarction has been reported in a number of studies, but such cardiotoxicity in Chinese patients with malignant diseases has not been investigated to date. In the present study, we aimed to prospectively evaluate the incidence rates and clinical manifestations of 5‐FU‐ and capecitabine‐associated cardiotoxicity in cancer patients recruited from multiple centers in China. Methods Among the 527 patients who completed the study, 196 received 5‐FU‐based chemotherapy and 331 received capecitabine‐based chemotherapy as either first‐line or adjuvant therapy. Adverse events were reported during the treatment and up to 28 days of follow‐up. Outcome measures included ECG, myocardial enzymes, cardiac troponin, brain natriuretic peptide and echocardiography. Univariate analysis and logistic regression were performed for subgroup analysis and identification of significant independent variables that are associated with cardiotoxicity of both agents. Results In total, 161 of 527 patients (30.6%) experienced cardiotoxicity. The incidence rate of cardiotoxicity was 33.8% (112/331) in the capecitabine group, which was significantly higher than the rate of 25% (49/196) in the 5‐FU group ( P = 0.0042). 110/527 patients (20.9%) suffered arrhythmia, 105/527 (19.9%) developed ischemic changes, while only 20/527 patients (3.8%) presented heart failure and 6/527 patients (1.1%) had myocardial infarction. Pre‐existing cardiac disease, hypertension, capecitabine‐based chemotherapy and duration of treatment were identified as significant risk factors associated with cardiotoxicity. The odds ratio were 15.7 (prior history of cardiac disease versus no history), 1.86 (capecitabine versus 5‐FU), 1.06 (5–8 versus 1–4 chemotherapy cycles) and 1.58 (hypertension versus no hypertension), respectively. Conclusions Cardiotoxicity induced by fluoropyrimidines in the Chinese population may be underestimated in clinical practice. Close monitoring of patients is recommended, especially for those patients at high risk for cardiotoxicity. Possible risk factors are duration of treatment, capecitabine‐based chemotherapy, pre‐existing cardiac diseases and hypertension. Trial registration This study was initiated on January 22, 2014 and has been retrospectively registered with the registration number ChiCTR1800015434" @default.
• W2800604403 created "2018-05-17" @default.
• W2800604403 creator A5001864411 @default.
• W2800604403 creator A5003807314 @default.
• W2800604403 creator A5007169885 @default.
• W2800604403 creator A5008421878 @default.
• W2800604403 creator A5010422757 @default.
• W2800604403 creator A5013628889 @default.
• W2800604403 creator A5021499700 @default.
• W2800604403 creator A5026544444 @default.
• W2800604403 creator A5033411376 @default.
• W2800604403 creator A5035132421 @default.
• W2800604403 creator A5040527192 @default.
• W2800604403 creator A5045305534 @default.
• W2800604403 creator A5052022256 @default.
• W2800604403 creator A5054986286 @default.
• W2800604403 creator A5071672663 @default.
• W2800604403 creator A5091366811 @default.
• W2800604403 date "2018-05-11" @default.
• W2800604403 modified "2023-10-17" @default.
• W2800604403 title "Cardiotoxicity of 5-fluorouracil and capecitabine in Chinese patients: a prospective study" @default.
• W2800604403 cites W100634000 @default.
• W2800604403 cites W152082071 @default.
• W2800604403 cites W1871377835 @default.
• W2800604403 cites W1910716144 @default.
• W2800604403 cites W1964317600 @default.
• W2800604403 cites W1967573251 @default.
• W2800604403 cites W1967628954 @default.
• W2800604403 cites W1968207082 @default.
• W2800604403 cites W1987526599 @default.
• W2800604403 cites W1989753015 @default.
• W2800604403 cites W2017827047 @default.
• W2800604403 cites W2023241123 @default.
• W2800604403 cites W2028359348 @default.
• W2800604403 cites W2055207859 @default.
• W2800604403 cites W2056236132 @default.
• W2800604403 cites W2072947041 @default.
• W2800604403 cites W2077425617 @default.
• W2800604403 cites W2081302357 @default.
• W2800604403 cites W2108522544 @default.
• W2800604403 cites W2110519215 @default.
• W2800604403 cites W2119270435 @default.
• W2800604403 cites W2119881391 @default.
• W2800604403 cites W2121976791 @default.
• W2800604403 cites W2127762172 @default.
• W2800604403 cites W2129967236 @default.
• W2800604403 cites W2136571540 @default.
• W2800604403 cites W2149771890 @default.
• W2800604403 cites W2166041370 @default.
• W2800604403 cites W2222720953 @default.
• W2800604403 cites W2235370487 @default.
• W2800604403 cites W2346599239 @default.
• W2800604403 cites W2395851371 @default.
• W2800604403 cites W2396646859 @default.
• W2800604403 cites W2464959044 @default.
• W2800604403 doi "https://doi.org/10.1186/s40880-018-0292-1" @default.
• W2800604403 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5953402" @default.
• W2800604403 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29764506" @default.
• W2800604403 hasPublicationYear "2018" @default.
• W2800604403 type Work @default.
• W2800604403 sameAs 2800604403 @default.
• W2800604403 citedByCount "33" @default.
• W2800604403 countsByYear W28006044032019 @default.
• W2800604403 countsByYear W28006044032020 @default.
• W2800604403 countsByYear W28006044032021 @default.
• W2800604403 countsByYear W28006044032022 @default.
• W2800604403 countsByYear W28006044032023 @default.
• W2800604403 crossrefType "journal-article" @default.
• W2800604403 hasAuthorship W2800604403A5001864411 @default.
• W2800604403 hasAuthorship W2800604403A5003807314 @default.
• W2800604403 hasAuthorship W2800604403A5007169885 @default.
• W2800604403 hasAuthorship W2800604403A5008421878 @default.
• W2800604403 hasAuthorship W2800604403A5010422757 @default.
• W2800604403 hasAuthorship W2800604403A5013628889 @default.
• W2800604403 hasAuthorship W2800604403A5021499700 @default.
• W2800604403 hasAuthorship W2800604403A5026544444 @default.
• W2800604403 hasAuthorship W2800604403A5033411376 @default.
• W2800604403 hasAuthorship W2800604403A5035132421 @default.
• W2800604403 hasAuthorship W2800604403A5040527192 @default.
• W2800604403 hasAuthorship W2800604403A5045305534 @default.
• W2800604403 hasAuthorship W2800604403A5052022256 @default.
• W2800604403 hasAuthorship W2800604403A5054986286 @default.
• W2800604403 hasAuthorship W2800604403A5071672663 @default.
• W2800604403 hasAuthorship W2800604403A5091366811 @default.
• W2800604403 hasBestOaLocation W28006044031 @default.
• W2800604403 hasConcept C121608353 @default.
• W2800604403 hasConcept C126322002 @default.
• W2800604403 hasConcept C164705383 @default.
• W2800604403 hasConcept C188816634 @default.
• W2800604403 hasConcept C2776694085 @default.
• W2800604403 hasConcept C2777909004 @default.
• W2800604403 hasConcept C2778213512 @default.
• W2800604403 hasConcept C2778233292 @default.
• W2800604403 hasConcept C500558357 @default.
• W2800604403 hasConcept C526805850 @default.
• W2800604403 hasConcept C71924100 @default.
• W2800604403 hasConceptScore W2800604403C121608353 @default.
• W2800604403 hasConceptScore W2800604403C126322002 @default.

• next